Physician profile
Stephen L Cornwell
NPI 1386713063
$736.75
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $616 · 2020: $121.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $194.56 | 2019 | |
| Novo Nordisk INC | $139.76 | 2019-2020 | |
| Lilly USA, LLC | $99.15 | 2019-2020 | |
| Sanofi Pasteur INC. | $44.39 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $39.43 | 2019 | |
| Astellas Pharma US INC | $34.13 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $32.45 | 2019 | |
| Glaxosmithkline, LLC. | $30.96 | 2019 | |
| Allergan, INC. | $24.45 | 2019 | |
| Merck Sharp & Dohme LLC | $23.18 | 2019 | |
| Gilead Sciences, INC. | $23.03 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $22.74 | 2019 | |
| Adlon Therapeutics L.P. | $16.43 | 2020 | |
| Amarin Pharma, INC. | $12.09 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Cornwell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.